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Summary The effects of suramin, an inhibitor of growth factor mitogenic activity, were evaluated on basic
fibroblast growth factor (bFGF)-induced proliferation of bovine aortic endothelial cells and on angiogenesis in
the chorioallantoic membrane (CAM) of chick embryos. The role of bFGF gene expression in endothelial cell
growth was also investigated by using an antisense oligodeoxynucleotide to bFGF. The 4-fold increase in
[3H]-thymidine uptake in endothelial cells in vitro upon stimulation with 10 ng ml-' of bFGF was inhibited by
suramin 300 jg ml-'. bFGF antisense oligomer (IOjiM) reduced [3H]-thymidine incorporation in exponentially
growing cells by 76%; this effect was reversed by bFGF 10 ng ml-'. In the CAM of chick embryos suramin
50 jug was a more potent inhibitor of angiogenesis than the combination of heparin 60 jg/hydrocortisone
50 jig; the mean value of the area with reduced vascularity was significantly larger in suramin-treated CAMs
(2.4 cm2) than in heparin/hydrocortisone (0.6 cm2), while the reduction of vascular density was similar (- 35
and - 29% compared to controls, respectively), In conclusion, the effects of treatments with bFGF and bFGF
antisense oligomer demonstrate that bFGF plays a relevant role in endothelial cell proliferation and may be
the target of suramin since the drug is able to suppress basal and bFGF-induced endothelial cell growth; in
addition to this, suramin is a more potent angiogenesis inhibitor in the CAM than the combination of
heparin/hydrocortisone.
There is now substantial evidence that tumour growth is
angiogenesis dependent and the intensity of neovascularisa-
tion is highly correlated with the metastatic outcome
(Weidner et al., 1991). Tumour-related angiogenesis is a well-
recognised, although not well-understood phenomenon (for
review see Folkman, 1990). The growth of solid tumours
beyond microscopic clumps of cells requires the development
of a vascular network, and convincing evidence has been
presented that this neovascularisation is the direct result of
tumour-derived angiogenesis-stimulating factors (for review
see Risau, 1990). Among them are wide-spectrum mitogens
including basic fibroblast growth factor (bFGF) (Hayek et
al., 1987), transforming growth factor-a (TGF-a) and epider-
mal growth factor (EGF) (Schreiber et al., 1986). Other
peptides apparently induce angiogenesis indirectly (e.g. trans-
forming growth factor-a, TGF-1) by stimulating target cells
to release angiogenic factors (Wiseman et al., 1988).
Recognition of the potential therapeutic benefit of suppres-
sing uncontrolled capillary growth has led to a search for
effective antiogenesis inhibitors. Fumagillin analogues (Ingber
et al., 1990), x-interferon and some antineoplastic agents
(Maione & Sharpe, 1990), and antioestrogens (Gagliardi &
Collins, 1993) have been shown to inhibit angiogenesis in
several experimental models. Suramin, a polysulfonated
naphthylurea reported to have clinical antitumour activity
(Stein et al., 1989; Myers et al., 1992), was found to block
the binding of a number of growth factors to their receptors,
including bFGF, TGF-P and EGF (Coffey et al., 1987;
Yayon & Klagsbrun, 1990). For these pharmacodynamic
properties suramin could be a candidate drug for
angiogenesis inhibition.
The aim of the present study was to document the effects
of suramin on basal and bFGF-stimulated proliferation of
endothelial cells and an angiogenesis in the chorioallantoic
membrane of chick embryos (CAM).
Materials and methods
Chemicals and mediafor cell culture
Heparin sodium, hydrocortisone 21-phosphate disodium salt,
bovine serum albumin fraction V (BSA), salmon sperm
DNA, reagents for SDS-PAGE, ethanol, ammonium acetate,
Fe2+-saturated transferrin, low-melting temperature agarose,
reagents for total cellular RNA extraction and analysis, and
recombinant human bFGF were from Sigma Chemicals Co.
(St. Louis, MO, USA). Other reagents used in the present
study were: minimum essential medium Eagle with Earle's
salts (MEM), Dulbecco's modified Eagle's medium
(DMEM), heat-inactivated foetal bovine serum (H-FBS),
phosphate-buffered saline (PBS) pH 7.4, L-glutamine,
antibiotics, 0.05% trypsin and 0.02% EDTA in Hank's
balanced salt solution Ca2+ and Mg2+-free (HBSS) (Flow,
Irvine, Scotland); chemicals or HPLC and trichloroacetic
acid (TCA) (Fluka AG, Buchs, Switzerland); [3H]-thymidine
(70-90 Ci mmol-') and [y-32P]ATP (6,000 Ci mmol-') (NEN-
Dupont, Wilmington, DE, USA) and reagents for oligo-
deoxynucleotide synthesis (Applied Biosystems, Foster City,
CA, USA). Plastics for cell culture were from Costar (Cam-
bridge, MA, USA). Suramin sodium was supplied by Bayer
(Leverkusen, Germany); the drug was dissolved in sterile
distilled water and stored at 4°C protected from the light
until its use.
Synthesis of the antisense oligodeoxynucleotides targeted
against bFGF
bFGF antisense (Becker et al., 1989) and random phos-
phorothioate oligodeoxynucleotides were synthesised on a
multiple-column, automated DNA synthesiser (Applied
Biosystems, Foster City, CA, USA) at 1.0timol synthesis
scale. Oligomers were purified on denatured acrylamide gels,
electroeluted and further purified by several cycles of
precipitation with ethanol saturated with ammonium acetate;
purity was also checked by reverse-phase HPLC. Concentra-
tions of oligodeoxynucleotides were determined spectro-
photometrically by absorbance at 260 nm, taking into
account the molar extinction coefficient of the nucleotides
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present in each sequence. The random sequence oligodeoxy-
nucleotide was used as a control in cell proliferation
experiments.
Bovine aortic endothelial cell cultures
Cloned populations of endothelial cells were established from
the intima of bovine aorta as described (Gospodarowicz et
al., 1976). Stock cultures were grown in 35 mm culture dishes
in DMEM containing glucose (1 gl'), H-FBS (10%), L-
glutamine (2 mM), penicillin (50 IU ml-') and streptomycin
(50 Lg ml-'); bFGF (2 ng ml-') was added every other day.
Cells were never allowed to reach confluency to avoid contact
inhibition of growth and cells in exponential growth phase
were either used for experiments or subcultured (up to ten
subcultures) at a split ratio of 1:15. Cells were harvested by
mild trypsinisation to minimise injury; monolayers were
washed with PBS, dissociated with trypsin-EDTA in HBSS
for 1-5 min at 4°C and finally washed with complete
medium. Cells were resuspended in DMEM with supplements
and cultured at 37°C, 5% CO2 atmosphere. Cells were also
evaluated for bFGF gene expression by Northern blot hybri-
disation. Total cellular RNA was extracted using the
guanidine isothiocyanate-cesium chloride method (Sambrook
et al., 1989). RNA (30 rig/lane) was size-fractionated by
0.66 M formaldehyde-l1.1% agarose gel elctrophoresis, trans-
ferred to nitrocellulose membranes, and hybridised by stan-
dard techniques to a 32P-labelled 25-mer oligodeoxynucleotide
probe synthesised on the basis of a previous report
(Abraham et al., 1986). Each filter was also hybridised with a
human y-actin probe to normalise for the amounts ofmRNA
transferred. The blots were then autoradiographed for 16 h at
- 75°C with intensifying screens. As positive control cell
expressing the bFGF gene message, the DUI45 prostate
cancer cell line (ATCC, Rockville, MD, USA) was used
(Nakamoto et al., 1992).
Quiescent endothelial cells were obtained as described (Bal-
din et al., 1990). Briefly, cells were seeded at low density (103
cells cm-2) in 24-well plates in complete medium containing
bFGF (2 ng ml-'); after 72 h they were washed twice with
serum-free DMEM containing Fe2+-saturated transferrin
(10ltgml-') and cultures were continued in the same
medium for 48 h. Cell cycle analysis was performed as
reported (Pontzer et al., 1991) to confirm the synchronisation
of cells into GOG, phase. Propidium iodide stained nuclei
were analysed on a FACStar (Becton Dickinson, San Jose,
CA, USA) using the CellFIT Cell-Cycle Analysis 2.0.2 soft-
ware; in these conditions, 95% of cells were in GOG, phase,
1.5% in S and 3.5% in G2M phase.
Effects by bFGF, suramin and antisense bFGF on endothelial
cellproliferation
Cell proliferation was assayed by measuring the incorpora-
tion of [3H]-thymidine into the DNA. GI -*mitosis transition
of quiescent endothelial cells was obtained by stimulation of
cells with DMEM containing 0.4% H-FBS, 3.5 mg/l00 ml
BSA and bFGF (0.5, 1, 5, 10 and 50 ng ml-'). Twenty-two
hours after bFGF addition, cells were pulse-labelled for 2 h
with 2 ytCi ml-' of [3H]-thymidine. To terminate the reaction,
cells were washed twice with ice-cold PBS, extracted with
10% (wt/vol) cold TCA and lysed with 0.25 N NaOH con-
taining 4 mg/l00 ml of salmon sperm DNA. Radioactivity
was measured by resuspending 0.5 ml of the cell lysate in
10 ml of Ecoscint A (National Diagnostics, Manville, NJ,
USA) and counted with a Packard 2000CA Tri-Carb liquid
scintillation counter (Packard Instrument Co., Downers
Grove, IL, USA). Flow cytometric analysis of exponentially
growing cells in complete medium and of cells in serum-free
culture stimulated by bFGF demonstrated that 60 and 75%
of cells were in GoG, phase, respectively. To evaluate the
effect of suramin on basal and bFGF-induced DNA syn-
thesis, 300 ytg ml-' of suramin were added 6 h before bFGF;
then the experiment was continued as reported above. The
effect of sense and antisense bFGF oligodeoxynucleotides on
endothelial cell proliferation was evaluated on cells in
exponential growth phase treated for 2 days with oligodeoxy-
nucleotides (10, 20 and 40 LM) which were added immedi-
ately after seeding and 24h thereafter. At the end of the
second day of treatment, cells were pulse-labelled for 2 h with
2fiCi ml-' of [3H]-thymidine and radioactivity was extracted
and counted as reported above.
Furthermore, to assess the reversibility of the inhibition of
cell proliferation by bFGF antisense oligodeoxynucleotide,
bFGF (1Ong ml-1) was added 2 h after each antisense addi-
tion and cell proliferation was evaluated as reported above.
Assay ofangiogenesis in the chick chorioallantoic membrane
model
The shell-less embryo culture used in the present study is an
adaptation of the procedure previously decribed (Vu et al.,
1985). Briefly, fertilised white Leghorn chick eggs were
incubated for 3 days and then washed in Betadine® and 70%
ethanol, cracked and the shell was separated from the em-
bryos under a laminar flow hood. The embryos were placed
in a plastic wrap-tripod apparatus modified from that des-
cribed elsewhere (Dunn et al., 1981). This consisted of a Petri
dish cover, a plastic wrap/plexiglass midportion, and a
humidifying plastic base. A Handiwrap plastic wrap (Dow
Chemical Company, Indianapolis, IN, USA) was suspended
within the chamber and formed a cradle for the contents of
the egg; the humidifying base contained 1% CuSO4*5H20 to
retard fungal growth. Four ml of MEM containing L-glut-
amine (2 mM), penicillin (50 IU ml-') and streptomycin
(50 ytg ml-') were added to the egg contents that were
delivered to the assembled sterile culture chambers. Embryos
were incubated at 37.5°C at a humidity of 50% for 3 days, at
which point treatments to assay angiogenesis inhibition were
started.
Preparation ofagarose disks and treatment ofCAM
Drugs were included into low-melting point agarose for sus-
tained release, as previously reported (Dobson et al., 1990).
Agarose was dissolved and sterilised by autoclaving; the solu-
tion was cooled and kept at 38°C in a water bath, thereby
avoiding any abnormal heating for the test drug to be added.
Suramin, heparin and hydrocortisone were added and
agarose solutions were poured on the surface of a 35 mm
sterile plastic dishes and placed at 4°C to solidify. Agar was
cut into round disks (diameter 5 mm and volume 25fsl) and
peeled away from the dish by a sterile spatula. The concen-
tration of agarose was 2.5% and each disk contained either
suramin (25, 50 or 100pg) or heparin (60 or 120pg)/
hydrocortisone (50 or 100jig). Disks were placed on the
CAM of chick embryos which were returned to the incubator
for 2 additional days. At the end of treatment, agarose disks
were gently removed and assayed for drug release while
embryos were sacrificed for quantitation of CAM vascular
network.
Quantitation ofchick chorioallantoic membrane vascularisation
The method described herein is an adaptation to the CAM of
the procedure described in detail elsewhere (Proia et al.,
1988). After two days of treatment, a 20% fat emulsion for
intravenous injection (Lipofundin 20, Braun Melsungen AG,
Germany) was injected into chorioallantois of chicken em-
bryos, so that the red colour of blood vessels contrasted
sharply with the white colour; CAMs were photographed
using a Polaroid model MP-4 camera system equipped with
105 mm objective.
Quantitation of angiogenesis inhibition was performed by
an image analysis system. Briefly, each print of the same
magnification was converted into a television image, and the
digitised data were analysed as discrete values of varying
shades of gray with an image analyser. This procedure
allowed the resolution of faint boundaries of vessels; nonvas-
cular noise was removed either by automatic cleaning process934 R. DANESI et al.
or by interactive use of an editor which could refine outlines
of the boundaries. Components of the image analysis system
were: image analyser ASBA (Wild + Leitz AG, F.R.G.), CD
233 monitor (BARC Industries, Belgium) and Polaroid
freeze-frame video recorder. One cm2 of the image array
contained 1509 pixels and 270-290 different gray levels could
be distinguished for each pixel. Using the digitiser tablet, a
line was drawn to delineate the total perimeter of both CAM
and treated area showing reduction of vascular network.
Modification of blood vessel density due to treatments was
estimated by a gray-scale analysis: the mean gray level of
each treated area was computed and expressed as percent
value compared to the mean gray level of the untreated
CAM.
Assessment ofdrug releasefrom agarose disks
Agarose disks were removed from the CAM at the end of
treatment, gently homogenised with few strokes of a Dounce
homogeniser with tight-fitting glass pestle at 550 rpm, and
the volume of homogenate was brought to 0.3 ml with dis-
tilled water. Suramin was measured by a reverse-phase, ion-
paring HPLC method (Supko & Malspeis, 1990) with
fluorimetric detection. Heparin was assayed in samples by a
colorimetric method (Khan & Newman, 1990) and the
residual amount of hydrocortisone in disks was measured by
a specific radioimmunologic method (Schiebinger et al.,
1986).
Statistical analysis
Results are given in the text as mean values unless otherwise
specified. Data reported in graphs are mean values ± s.e.m.
of n experiments. The effects of suramin and heparin/
hydrocortisone on vascular network development and the
resulting hypovascular area of CAM were compared with
two-tailed Student's t-test for unpaired data (Zar, 1984). A P
value less than 0.05 was considered to be significant.
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Figure 1 Northern blot analysis of bFGF transcripts in
endothelial cells a, and positive control DU145 prostate cancer
cells b. Total RNA (30 gg/lane) was size-fractionated on a 0.66 M
formaldehyde-1.1% agarose gel electrophoresis, transferred to
nitrocellulose membranes, and hybridised by standard techniques
to the 32P-labelled oligomer probe. Blots were also probed with a
human y-actin probe c, to normalise for the amounts of RNA
loaded. bFGF transcripts (3.7 and 7 kb) are shown by arrows.
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Results
Modulation ofendothelial cellgrowth by suramin, bFGF and
bFGF antisense oligomer
Northern blot analysis of total cellular RNA demonstrated
the presence of bFGF transcripts (3.7 and 7 kb) in
endothelial cells used in the present study (Figure 1). In
quiescent cells (1.5% of cells in S phase), [3H]-thymidine
incorporation was stimulated when cells were exposed to
bFGF; the increase peaked at 10 ng ml-' ( + 390% com-
pared with controls) with 5% cells in S phase and remained
considerably elevated at 50 ng/ml (Figure 2). Therefore, the
effect of suramin on the mitogenic activity of bFGF on
endothelial cells was evaluated. Suramin 300 gIg ml-' added
to the culture medium 6 h before bFGF almost completely
inhibited the growth factor-induced cell proliferation (Figure
2). The effect of blocking the expression of bFGF gene was
evaluated by using the antisense oligomer targeted against
bFGF mRNA which was added to cell cultures in exponen-
tial growth phase. A 76% inhibition of [3H]-thymidine incor-
poration into DNA was obtained after 48 h treatment with
1OIM of bFGF antisense oligomer (Figure 3). To demon-
strate that its antiproliferative effect was sequence-specific,
cells were exposed to the random sequence oligomer; under
this condition, no significant inhibition of cell growth could
be demonstrated. In addition to this, the inhibitory effect of
antisense treatment was partially reversed by treatment with
bFGF 10ng ml-' (Figure 3).
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Figure 2 Stimulation of [3H]-thymidine incorporation into DNA
of endothelial cells by bFGF and its inhibition by suramin.
Quiescent cells were stimulated with D-MEM containing 0.4%
H-FBS, 3.5 mg/100 ml BSA and bFGF 0.5, 1, 5, 10 and
50 ng ml-' (white circles). Twenty-two hours after bFGF addi-
tion, cells were pulse-labelled for 2 h with 2fiCi ml-' of [3H]-
thymidine. Radioactivity was measured in TCA precipitable
material by liquid scintillation counting. In experiments involving
suramin (black circles), the drug (300 .gml-') was added to the
culture medium 6 h prior to bFGF.
Angiogenesis inhibition in the chick chorioallantoic membrane
Chick embryo survival until disk implantation was approx-
imately 67% with a 14% loss during removal from the shell
and a subsequent loss of 19% due to either infection or
abnormal differentiation, in agreement with an earlier pub-
lished report (Woltering et al., 1991). After 2 days of treat-
ment, the branching pattern of blood vessels below disks
containing heparin 60 gg/hydrocortisone 50,ug was reduced
(Figure 4a); based on the gray-scale analysis, the mean
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Figure 3 Inhibition of [3H]-thymidine incorporation into DNA
of endothelial cells by antisense oligomer against bFGF mRNA
and reversal by bFGF. Cells in exponential growth phase were
treated twice at 24 h intervals with graded concentrations of the
antisense (white squares) and random (white circles) oligomers.
At the end of the second day of treatment, cells were pulse-
labelled for 2 h with 2 tCi ml-' of [3H]-thymidine and radioac-
tivity was measured into TCA precipitable material by liquid
scintillation counting. bFGF 10ng ml-' (black squares) was
added 2 h after each oligomer addition and cell proliferation was
evaluated as reported above.
absolute values of vascular densities of control and treated
CAMs were 112 and 79 respectively, which corresponded to
a 29% decrease over an area of 0.6 cm2 (Figure 5). In the
CAM around the disks containing suramin 50plg the tiny
vessel loops were absent (Figure 4b) and the mean gray-scale
value was 72, corresponding to a 35% inhibition over a
surface of 2.4 cm2 (Figure 5). In both treatments, the faint
boundaries and capillaries of CAM were severely affected,
while the larger vessels were reduced in caliber. The reduc-
tion in vascular density was slightly more pronounced in
suramin-treated CAMs, but the difference with heparin/
hydrocortisone was not significant (Figure 5). However, the
area showing a decrease in vascularisation was significantly
larger after exposure to suramin than to heparin/hydro-
cortisone (Figure 5). A lower amount of suramin (25ILg/disk)
produced a modest antiangiogenic effect; the mean gray-scale
value was 95 indicating a 15% reduction of vascular density
compared to controls and the mean value of the area with
reduced vascular density was 0.8 cm2. Higher amounts of
suramin (100jtg) or heparin (120jig)/hydrocortisone (100Ag)
included in agarose disks were associated with a marked
reduction in chick embryo survival (less than 2 days) due to
thrombosis, hemorrhage or marked distortion of large
vessels. Therefore, in our analysis, suramin 50 tg or heparin
60fLg/hydrocortisone 50 ig represented the optimum doses
with maximum antiangiogenic activity and embryo survival.
Moreover, microscopic examination of CAMs treated with
suramin 50fLg did not reveal thrombi in large vessels. The
reason for the decrease in vascularisation and the disap-
pearance of capillaries (thrombosis or failure to form blood
vessels) could not be demonstrated. In each case, if the
agarose disks were removed and the CAMs were allowed to
recover for 2-4 days, the avascular area was substantially
unchanged with respect to vascular density and surface (data
not shown). The area of CAM below control disks without
drugs did not show changes in vascular density with a nor-
mal leaf-life branching pattern of blood vessels (Figure 4c),
indicating that the disk weight did not affect their growth
during the experiment.
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Figure 4 Computer-generated images derived from CAMs after
a 2-day treatment with agarose disks containing heparin 60 tLg/
hydrocortisone 50gLg a, suramin 50gig b, or vehicle control c. The
white colour corresponds to the CAM with reduction of blood
vessels density (circumferential arrowheads) while the gray colour
corresponds to the normal CAM. In each case, the position and
dimension of the agarose disks are identified by small rings. The
bar at the bottom of each picture corresponds to 1 cm.
Agarose disks provided an inert support for drug delivery;
at the end of their permanence on the CAM, the mean
percentage value ofdrug released was 54.6, 80.2, and 60.4 for
heparin, hydrocortisone and suramin, respectively (Table I).936 R. DANESI et al.
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Figure 5 Decrease in vascular density and extension of the area
of CAM treated with suramin 50 gIg (white bars) or heparin
60 gig/hydrocortisone 50 gLg (black bars). Differences in vascular
density of treated vs untreated CAMs were calculated by analys-
ing the digitised data as discrete values of varying shades of gray
with the aid of an image analysis system; the same system
allowed the measurement of the area with reduced blood vessel
density. *P<0.05.
Discussion
The antitrypanosomal drug suramin selectively dissociates
several heparin-binding growth factors from their receptors
and produces antiproliferative effects on cancer cells both in
vitro and in vivo (for review see La Rocca et al., 1990). These
effects were proposed to occur by inhibition of growth factor
receptor binding or by a modified interaction between growth
factor receptor and autosecreted oncogene products (Mos-
catelli & Quarto, 1989). bFGF is an heparin-binding mitogen
that plays a central role in tumour development and meta-
statis (Becker et al., 1989). It affects the growth of many cell
types via high affinity membrane receptors and is a potent
endothelial growth factor capable of inducing the formation
of new capillary blood vessels in vivo at nanogram amounts
(Risau et al., 1990). Inhibition of angiogenesis by means of
bFGF immunoneutralising monoclonal antibody has been
reported to be associated with antitumour effect in vivo (Hori
et al., 1991), suggesting that novel therapeutic approaches to
cancer therapy might involve the use of antiangiogenic drugs.
The results of the present study indicate that bFGF gene
message is detectable in the endothelial cells and that cells
have bFGF as a mitogenic factor. Further evidence on the
possible autocrine role of bFGF on endothelial cells is sug-
gested in the present study where an antisense oligomer
targeted against bFGF mRNA, a specific tool of inhibition
of gene expression (Helene & Toulme, 1990), markedly
reduces the [3H]-thymidine incorporation in exponentially
growing cells. The effect was partially inhibited by the subse-
quent addition of exogenous bFGF in the culture medium.
Suramin and antisense oligomers appear to be drugs acting
at two different levels of bFGF mitogenic activity; suramin
acts primarily at the level of cell surface receptors, while the
antisense oligomer exerts its effect intracellularly at the level
of mRNA processing (Helene & Toulme, 1990).
The biologic activity of bFGF is the result of the interac-
tion of the growth factor released in the endoplasmic
reticulum with specific receptors or the secretion of bFGF in
the extracytoplasmic compartment and binding to cell surface
receptors. Even if bFGF lacks the secretory signal sequence
and is primarily retained intracellulary, bFGF is also released
in the extracellular compartment (Mignatti & Rifkin, 1991).
Suramin at a concentration of 300 fg ml-', a clinically
effective drug level, is able to suppress bFGF proliferative
activity on endothelial cells. At least two previously pub-
lished works describe the inhibitory effect of suramin on
bFGF biologic activity (Sato & Rifkin, 1988; Moscatelli &
Quarto, 1989) and one of them describes the effects of bFGF
on bovine endothelial cell motility and DNA synthesis. The
data of the above-mentioned reports, however, were obtained
with: (i) a very high level of suramin (0.75-1 mM correspon-
ding to 1. -1.4 mg ml-'), and (ii) a low protein concentra-
tion (1% FBS) in the culture medium. Suramin plasma levels
in patients should not exceed 300 fig ml- (approximately
0.21 mM) (La Rocca et al., 1990) to reduce the risk of severe
neurotoxicity and many of the drug's biological properties
(e.g. the antiproliferative activity) are dependent on protein
concentration in culture medium. This is due to its high
affinity for plasma proteins: more than 90% of the drug is
bound to albumin and other globulins (Hawking, 1978). As
we gain knowledge in the clinical use of suramin as a
chemotherapeutic agent, there is a need for a re-evaluation of
suramin's pharmacodynamic properties under adequate ex-
perimental conditions. In the present study, the results were
obtained in culture medium supplemented with 10% FBS
and with up to 5-fold less suramin concentration than that
used in previous studies.
The results presented herein demonstrate that after a 2-day
exposure to a single dose of suramin 50 lg/disk, the density
of normal developing vascular network in the CAM of chick
embryos was decreased by 35%; this effect was also produced
by heparin 60,ug/hydrocortisone 50 gg (- 29% compared to
normal CAM) and the difference between treatments was not
significant. Whether this effect is the result of a specific
inhibition of bFGF remains to be demonstrated. The
evidence that both suramin and heparin/hydrocortisone
inhibit the growth of blood vessels suggests that heparin-
binding angiogenic factors play an important role in
stimulating the growth of blood vessels in the CAM. The
major difference between treatments consisted of the exten-
sion of the hypovascular area; that under disks containing
suramin was significantly larger than that under heparin/
hydrocortisone. This effect might be dependent on the
diffusion of suramin out of the agarose disks and on the
resistance of the drug to metabolic degradation by living
organisms (La Rocca et al., 1990). On the contrary, the
effect of heparin/hydrocortisone seems to be confined to the
close proximity of the disks; this effect might be dependent
on degradation by cells or dilution of the drugs under con-
centrations critical to their activity. The amount of drugs
delivered by disks showed that suramin was even more
effective than heparin/hydrocortisone, since the released
amount of the former drug was 29.1 ± 2.2 tig while that of
the latter combination was 34.1 ± 4.8 and 41.6 ± 3.6 gsg for
heparin and hydrocortisone, respectively. Due to the absence
of inflammatory reactions around the agarose disks and the
normal development of blood vessels under them, the present
study provide evidence that this support is a useful tool for
Table I Release of heparin, hydrocortisone and suramin from agarose disks used for delivering
drugs to the CAMa
Drug (pg) Before treatment After treatment Drug released Mean release (%0)
Heparin 62.5 ± 4.6 28.4 ± 3.9 34.1 ± 4.8 54.6
Hydrocortisone 51.9 ± 2.9 10.3 ± 1.2 41.6 ± 3.6 80.2
Suramin 48.2 ± 5.3 19.1 ± 1.1 29.1 ± 2.2 60.4
aDisks were applied on the CAM of chick embryos and removed 2 days later; drug content
(jLg) was assayed in n = 10 disks for each treatment as reported in the Materials and methods
section
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delivering drugs to the CAM. The angiostatic effect of
heparin, steroids and suramin was recently demonstrated in a
model of glass-fiber filter stimulated angiogenesis in the
CAM (Wilks et al., 1991). Suramin and heparin alone had a
modest angiostatic effect on the CAM; however the most
active single compound was cortisone acetate, followed by
other steroids. The addition of heparin or suramin to the
steroids produced an increase in the angiogenesis inhibition
(Wilks et al., 1991). Drug release from the inert support used
for drug administration, however, was not measured, thus
the comparison of the angiostatic effects might suffer from
the lack of these data. In the present study no angiogenesis
inhibition was found using heparin alone; only the addition
of hydrocortisone elicited the angiostatic effect of heparin, in
agreement with earlier reports (Folkman et al., 1983;
Maragoudakis et al., 1989; Lee et al., 1990). This might be
dependent on the different experimental conditions; the
angiogenesis induced in the CAM by glass-fiber filters (Wilks
et al., 1991) was inhibited by cortisone acetate, an agent used
by other authors to prevent the phlogistic reaction in the
CAM following the experimental manipulation (Maragoudakis
et al., 1989) and might be dependent at least in part on the
release of mediators of inflammation.
In conclusion, the present report shows that suramin is an
effective inhibitor of bFGF mitogenic activity in endothelial
cells and of angiogenesis in the CAM, suggesting an addi-
tional mechanism of the pharmacological activity of the drug
which could be relevant to its antitumour activity.
This work was supported in part by a generous contribution from
the Italian Association for Cancer Research (AIRC, Milano, Italy).
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